Tumor immunology

JAMA

Volumn 278, Issue 22, 1997, Pages 1972-1981

  Shu, Suyu ^a   Plautz, Gregory E ^a   Krauss, John C ^a   Chang, Alfred E ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

MAJOR HISTOCOMPATIBILITY ANTIGEN; TUMOR ANTIGEN;

ANTIGEN PRESENTATION; ANTIGEN RECOGNITION; ANTIGEN SPECIFICITY; CANCER IMMUNOLOGY; CANCER IMMUNOTHERAPY; CELL DIFFERENTIATION; CYTOTOXIC T LYMPHOCYTE; DISEASE ASSOCIATION; GENE EXPRESSION; GENE REARRANGEMENT; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNOGENICITY; IMMUNOTHERAPY; ONCOGENE; PASSIVE IMMUNIZATION; PRIORITY JOURNAL; PROTEIN ANALYSIS; REVIEW; SUPPRESSOR CELL; TUMOR IMMUNITY; TUMOR REJECTION; TUMOR SUPPRESSOR GENE; VIRUS GENE;

EID: 0031457120     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.278.22.1972     Document Type: Review

References (52)

1. Prehn RT, Main JM. Immunity to methylcholanthrene-induced sarcomas. J Natl Cancer Inst. 1957; 18:769-778.
2. Hewitt HB, Blake ER, Walder AS. A critique of the evidence for active host defense against cancer, based on personal studies of 27 murine tumors of spontaneous origin. Br J Cancer. 1976;33:241-259.
3. Aaltomaa S, Lipponen P, Eskelinen M, et al. Lymphocyte infiltrates as a prognostic variable in female breast cancer. Eur J Cancer. 1992;28A:859-864.
4. Pastorfide GC, Kibbi AG, de Roa AL, et al. Image analysis of stage 1 melanoma (1.00-2.50 mm): lymphocytic infiltrates related to metastasis and survival. J Cutan Pathol. 1992;19:390-397.
5. Rosenberg SA, Spiess P, Lafreniere R. A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science. 1986; 283:1318-1321.
6. Celis E, Tsai V, Crimi C, et al. Induction of anti-tumor cytotoxic T lymphocytes in normal humans using primary cultures and synthetic peptide epitopes. Proc Natl Acad Sci U S A. 1993;91:2105-2109.
7. Boon T, Kellerman O. Rejection by syngeneic mice of cell variants obtained by mutagenesis of a malignant teratocarcinoma cell line. Proc Natl Acad Sci U S A. 1977;74:272-275.
8. Shu S, Chou T, Sakai K. Lymphocytes generated by in vivo priming and in vitro sensitization demonstrate therapeutic efficacy against a murine tumor that lacks apparent immunogenicity. J Immunol. 1989;143:740-748.
9. Miller AR, McBride WH, Hunt K, Economou JS. Cytokine-mediated gene therapy for cancer. Ann Surg Oncol. 1994;1:436-450.
10. Wallich R, Bulbuc N, Hammerling GJ, Katzav S, Segal S, Feldman M. Abrogation of metastatic properties of tumour cells by de no vo expression of H-2K antigens following H-2 gene transfection. Nature. 1985;315:301-305.
11. Chen L, McGowan P, Ashe S, et al. Tumor immunogenicity determines the effect of B7 costimulation on T cell-mediated tumor immunity. J Exp Med. 1994;179:523-532.
12. Dudley ME, Roopenian DC. Loss of a unique tumor antigen by cytotoxic T lymphocyte immune-selection from a 3-methylcholanthrene-induced mouse sarcoma reveals secondary unique and share antigens. J Exp Med. 1996;184:441-447.
13. Matsumura T, Sussman JJ, Krinock RA, Chang AE, Shu S. Characteristics and in vivo homing of long-term T-cell lines and clones derived from tumor-draining lymph nodes. Cancer Res. 1994;54: 2744-2750.
14. Tsang KY, Zaremba S, Nieroda CA, Zhu MZ, Hamilton JM, Schlom J. Generation of human cytotoxic T cells specific for human carcinoembryonic antigen epitopes from patients immunized with recombinant vaccinia-CEA vaccine. J Natl Cancer Inst. 1995;87:982-990.
15. McLaughlin JP, Schlom J, Kantor JA, Greiner JW. Improved immunotherapy of a recombinant carcinoembryonic antigen vaccinia vaccine when given in combination with interleukin-2. Cancer Res. 1996;56:2361-2367.
16. Fu YX, Watson GA, Kasahara M, Lopez DM. The role of tumor-derived cytokines on the immune system of mice bearing a mammary adenocarcinoma, I: induction of regulatory macrophages in normal mice by the in vivo administration of rGM-CSF. J Immunol. 1991;146:783-789.
17. Vinuela JE, Rodriguez R, Gil J, Coll J, Dela Concha EG, Subiza JL. Antigen shedding vs development of natural suppressor cells as mechanism of tumor escape in mice bearing Ehrlich tumor. Intl J Cancer. 1991;47:86-91.
18. North RJ. Down-regulation of the antitumor immune response. Adv Cancer Res. 1985;45:1-43.
19. Klarnet JP, Kern DE, Okuno K, Holt C, Lilly F, Greenberg PD. FBL-reactive CD8+ cytotoxic and CD4+ helper T lymphocytes recognize distinct friend murine leukemia virus-encoded antigens. J Exp Med. 1989;169:457-467.
20. Levine AM. Lymphoma complicating immunodeficiency disorders. Ann Oncol. 1994;2:29-35.
21. Peace DJ, Smith JW, Disis ML, Chen W, Cheever MA. Induction of T cells specific for the mutated segment of oncogenic p21ras protein by immunization in vivo with the oncogenic protein. J Immunother. 1993;14:10-14.
22. Canaani E, Marcelle C, Fainstein E. bcr-abl RNA in chronic myelogenous leukemia and lymphocytic leukemia. In: Deisseroth A, Arlinghaus RB, eds. Chronic Myelogenous Leukemia: Molecular Approaches to Research and Therapy, Part III. New York, NY: Marcel Dekker Inc; 1991.
23. Chen W, Peace DJ, Rovira DK, You S-G, Cheever MA. T-cell immunity to the joining region of p210BCR-ABL protein. Proc Natl Acad Sci U S A. 1992;89:1468.
24. Bocchia M, Korontsvit T, Xy Q, et al. Specific human cellular immunity to bcr-abl oncogene-derived peptides. Blood. 1996;87:3587-3592.
25. Van Pel A, van der Bruggen P, Coulie PG, et al. Genes coding for tumor antigens recognized by cytolytic lymphocytes. Immunol Rev. 1995;145:229-250.
26. Cheever MA, Disis ML, Bernhard H, et al. Immunity to oncogenic proteins. Immunol Rev. 1995; 145:33-59.
27. Houbiers JGA, Nijman HW, van der Burg SH, et al. In vitro induction of human cytotoxic T lymphocyte responses against peptides of mutated and wild type p53. Eur J Immunol. 1993;23:2072-2077.
28. Boon T, van der Burggen. Human tumor antigens recognized by T lymphocytes. J Exp Med. 1996; 183:725-729.
29. Rosenberg RA, White DE. Vitiligo in patients with melanoma: normal tissue antigens can be targets for cancer immunotherapy. J Immunother. 1996;19:81-84.
30. Bast RC Jr, Zbar B, Borsos T, Rapp HJ. BCG and cancer. N Engl J Med. 1974;290:1413-1420, 1458-1469.
31. Rosenberg SA, Lotze M, Yang J, et al. Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients. Ann Surg. 1989; 210:474-484.
32. Vieweg J, Gilboa E. Considerations for the use of cytokine-secreting tumor cell preparations for cancer treatment. Cancer Invest. 1995;13:193-201.
33. Dranoff G, Jaffe E, Lazenby A, et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting antitumor immunity. Proc Natl Acad Sci U S A. 1993;90:3539-3543.
34. Connor J, Bannerji R, Saito S, Heston W, Fair W, Gilboa E. Regression of bladder tumors in mice treated with interleukin 2 gene-modified tumor cells. J Exp Med. 1993;177:1127-1136.
35. Porgador A, Bannerji R, Watanabe Y, Feldman M, Gilboa E, Eisenbach L. Antimetastatic vaccination of tumor-bearing mice with two types of IFN-γ gene-inserted tumor cells. J Immunol. 1993;150: 1458-1470.
36. Chen L, Ashe S, Brady WA, et al. Costimulation of antitumor immunity by the B7 counter receptor for the T lymphocyte molecule CD28 and CTLA-4. Cell. 1992;71:1093-1102.
37. Huang AYC, Bruce AT, Pardoll DM, Levitsky HI. Does B7-1 expression confer antigen presenting cell capacity to tumors in vivo? J Exp Med. 1996; 183:769-776.
38. Steinman RM. The dendritic cell system and its role in immunogenicity. Annu Rev Immunol. 1991; 9:271-296.
39. Paglia P, Chiodoni C, Rodolfo M, Colombo MP. Murine dendritic cells loaded in vitro with soluble protein prime CTL against tumor antigen in vivo. J Exp Med. 1996;183:317-322.
40. Hsu FJ, Benike C, Fagnoni F, et al. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat Med. 1996;2:52-58.
41. Murray JL, Rosenblum MG, Sobol RE, et al. Radioimmunoimaging in malignant melanoma using 111In-labeled monoclonal antibody 96.5. Cancer Res. 1985;45:2376-2381.
42. Kaminski MS, Zasadny KR, Francis IR, et al. Iodine-131-anti-B1 radioimmunotherapy for B-cell lymphoma. J Clin Oncol. 1996;14:1974-1981.
43. Morgan DA, Ruscetti FW, Gallo RC. Selective in vitro growth of T lymphocytes from normal human bone marrows. Science. 1976;193:1007-1008.
44. Grimm EA, Robb RJ, Roth JA, et al. Lymphokine-activated killer cell phenomenon, III: evidence that IL-2 is sufficient for direct activation of peripheral blood into lymphokine-activated killer cells. J Exp Med. 1983;158:1356-1361.
45. Rosenberg SA, Lotze MT. Cancer immunotherapy using interleukin-2 and interleukin-2-activated lymphocytes. Annu Rev Immunol. 1986;4: 681-709.
46. Spiess PJ, Yang JC, Rosenberg SA. In vivo activity of tumor infiltrating lymphocytes expanded in recombinant interleukin-2. J Natl Cancer Inst. 1987;79:1067-1075.
47. Rosenberg SA, Packard BS, Aebersold PM, et al. Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma: a preliminary report. N Engl J Med. 1988;319:1676-1680.
48. Rosenberg SA, Yannelli JR, Yang JC, et al. Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin-2. J Natl Cancer Inst. 1994;86:1159-1166.
49. Shu S, Chou T, Rosenberg SA. Generation from tumor-bearing mice of lymphoid cells with in vivo therapeutic efficacy. J Immunol. 1987;139: 295-304.
50. Chang AE, Yoshizawa H, Sakai K, Cameron MJ, Sondak VK, Shu S. Clinical observations on adoptive immunotherapy with vaccine-primed T lymphocytes secondarily sensitized to tumor in vitro. Cancer Res. 1993;53:1043-1050.
51. Yoshizawa H, Chang AE, Shu S. Specific adoptive immunotherapy mediated by tumor-draining lymph node cells sequentially activated with anti-CD3 and IL-2. J Immunol. 1991;147:729-737.
52. Chang AE, Aruga A, Cameron MJ, et al. Adoptive immunotherapy with vaccine-primed lymph node cells secondarily activated with anti-CD3 and IL-2. J Clin Oncol. 1997;15:796-807.